In the 10 years since neurotrophic activity was first reported for erythropoietin (EPO), a broad understanding of its multiple paracrine/autocrine functions has emerged. Recent studies firmly establish EPO as a multifunctional molecule, typical of the pliotrophic cytokine superfamily of which it is a member. The realization that EPO activates neuroprotection by multiple mechanisms has identified a generalized system of local tissue protection with EPO as a critical component. Here, the authors characterize the biology of the local tissue-protective system, review data that support this concept, and suggest why non-hematopoietic analogues of EPO may be better choices as therapeutics.
Get full access to this article
View all access options for this article.
References
1.
Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, and others. 2001. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res61: 3561-3565.
2.
Albayrak S, Zhao Q, Siesjo BK, Smith ML. 1997. Effect of transient focal ischemia on blood-brain barrier permeability in the rat: correlation to cell injury. Acta Neuropathol (Berl)94: 158-163.
3.
Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, and others. 1999. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab19: 643-651.
4.
Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, and others. 2000. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A97: 10526-10531.
5.
Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, and others. 2003. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A100: 4802-4806.
6.
Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, and others. 2000. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem275: 25130-25138.
7.
Chin K, Yu X, Beleslin-Cokic B, Liu C, Shen K, Mohrenweiser HW, and others. 2000. Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res81: 29-42.
8.
Dawson TM. 2002. Preconditioning-mediated neuroprotection through erythropoietin? Lancet359: 96-97.
9.
Digicaylioglu M, Lipton SA. 2001. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature412: 641-647.
10.
Ehrenreich H, Hasselblatt M, Lewczuk P, Dembowski C, Cepek L, Stiefel M, and others. 2002. Erythropoietin treatment for acute stroke: a randomized double-blind proof-of concept trial in man. Stroke33: 354.
11.
Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, and others. 2003. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A100: 6741-6746.
12.
Fisher JW. 2003. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood)228: 1-14.
13.
Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, and others. 2002. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to sub-arachnoid hemorrhage. Proc Natl Acad Sci U S A99: 5627-5631.
14.
Henson PM, Bratton DL, Fadok VA. 2001. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol2: 627-633.
15.
Juul S. 2002. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl91: 36-42.
16.
Leyland-Jones B. 2003. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol4: 459-460.
17.
Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, and others. 1997. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci17: 5395-5406.
18.
Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Jr., Tabira T, and others. 1993. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem268: 11208-11216.
19.
Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. 1997. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience76: 105-116.
20.
Nadal-Ginard B, Kajstura J, Anversa P, Leri A. 2003. A matter of life and death: cardiac myocyte apoptosis and regeneration. J Clin Invest111: 1457-1459.
21.
Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU. 2001. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol60: 386-392.
22.
Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, and others. 2000. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem275: 39754-39761.
23.
Prass K, Scharff A, Ruscher K, Lowl D, Muselmann C, Victorov I, and others. 2003. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke34: 1981-1986.
24.
Rivest S. 2003. Molecular insights on the cerebral innate immune system. Brain Behav Immun17: 13-19.
25.
Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, and others. 2002. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci22: 10291-10301.
26.
Savill J, Fadok V, Henson P, Haslett C. 1993. Phagocyte recognition of cells undergoing apoptosis. Immunol Today14: 131-136.
27.
Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H. 2001. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl)101: 271-276.
Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, and others. 1996. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem239: 494-500.
30.
Zaman K, Ryu H, Hall D, O’Donovan K, Lin KI, Miller MP, and others. 1999. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21 (waf1/cip1), and erythropoietin. J Neurosci19: 9821-9830.
